GlassScriptPhysician profile
Sonya Tran
NPI 1508423997
$1,871.84
in general payments reported to CMS, 2019-2025
16 companies · $594 in 2025
The $594 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.04 · 2022: $287 · 2023: $401 · 2024: $567 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $384.11 | 2022-2025 | Precision 1, Total30, Dailies Total1 |
| Coopervision INC. | $363.45 | 2022-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Mallinckrodt Hospital Products INC. | $210.47 | 2025 | Acthar |
| Johnson & Johnson Vision Care, INC. | $177.05 | 2022-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $138.26 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $123.26 | 2023-2025 | Cequa |
| Oyster Point Pharma, INC. | $115.97 | 2023-2024 | Tyrvaya |
| Abbvie INC. | $85.92 | 2022-2025 | Vuity |
| Dompe US, INC. | $75.67 | 2024-2025 | Oxervate |
| Horizon Therapeutics Plc | $46.40 | 2022-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $41.82 | 2023 | Lipiflow System Activator (Disposable) |
| Amgen INC. | $26.14 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.04 | 2021 | |
| Ani Pharmaceuticals, INC. | $21.56 | 2025 | Purified Cortrophin Gel |
| Bausch & Lomb Americas INC. | $20.72 | 2025 | Infuse |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.